News | February 02, 2026
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Subscribe To Our Newsletter & Stay Updated
